Wendell Wierenga

Wendell Wierenga is the current director at Cytokinetics. Wendell has over twenty years of experience in the pharmaceutical industry, holding various positions at different companies.

Wierenga started their career in pharmaceuticals at Onyx Pharmaceuticals, Inc. in 1996, where they worked their way up to director. In 2001, they left Onyx to become the director at XenoPort, Inc.

In 2011, Wierenga became the executive vice president of research and development at Santarus, Inc. Wendell held this position until 2014 when Santarus was acquired by Salix Pharmaceuticals.

After a brief break from the industry, Wierenga returned to pharmaceuticals in 2016 as a director at Patara Pharma. Wendell held this position until 2019 when Patara was acquired by Respivant.

Also in 2016, Wierenga became a director at Anacor Pharmaceuticals. Wendell held this position until Anacor was acquired by Pfizer in 2016.

Wierenga has been with Cytokinetics since 2013 and is currently their director.

Wendell Wierenga received their Doctor of Philosophy in Chemistry from Stanford University and their Bachelor of Arts in Chemistry from Hope College.